Splash Pharmaceuticals

Splash Pharmaceuticals, founded as a privately held company, is dedicated to developing novel cancer therapies with a focus on targeting CD44 to treat solid tumors. Their core mission is to provide dramatic and durable responses in oncology and arthritis patients through innovative treatments. Splash's pipeline includes agents with anti-angiogenic, anti-metastatic properties, and synergistic cytotoxicity when combined with other chemotherapy agents. The company is actively seeking partnerships to accelerate its clinical programs.

Notable figures affiliated with Splash Pharmaceuticals include experienced oncology researchers and industry veterans. The company has secured significant investments from venture capital firms specializing in biotech. Key achievements include the development of their lead candidate, SPL-, which has shown promising safety and efficacy in multiple clinical trials involving numerous human subjects. Splash's impact lies in its potential to revolutionize cancer and arthritis treatment by offering more effective and targeted therapies.